“Q&A with FDA” Podcast Series – Conversation on Paxlovid and COVID-19: Drug Information Update

Listen to "Q&A with FDA" Podcast Series - Conversation on Paxlovid and COVID-19

CENTER FOR DRUG EVALUATION AND RESEARCH DIVISION of DRUG INFORMATION Your source for the latest drug information. Know the moment it happens. "Q&A with FDA" Podcast Series  Conversation on Paxlovid and COVID-19 FDA/CDER's Division of Information (DDI) has launched a new monthly podcast series, "Q&A with FDA" providing engaging conversation and discussion surrounding trending regulatory topics. DDI responds to thousands of inquiries from the public every month.  In this new podcast series, we will be answering some of our most commonly received questions. Perhaps you have had the same questions but never asked. The first episode kicks off with a conversation with Dr. Farley, Director of CDER's Office of Infectious Diseases, discussing Paxlovid, an oral treatment in the management non-hospitalized adults with COVID-19.  Listen Here This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov. Stay Connected with U.S. Food and Drug Administration:         SUBSCRIBER SERVICES: Manage Subscriptions  |  Unsubscribe All  |  Help

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA